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Chromoblastomycosis is a subcutaneous mycosis that re-
mains a therapeutic challenge, with no standard treatment
and high rates of relapse. On the basis of our recent discov-
eries in mouse models, we tested the efﬁcacy of topical appli-
cations of imiquimod to treat patients afﬂicted with this
chronic fungal infection. We report results of treatment for
the ﬁrst 4 recipients of topical imiquimod, all of whom dis-
played a marked improvement of their lesions, both with and
without concurrent oral antifungal therapy.
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Chromoblastomycosis (CBM) is a chronic subcutaneous mycosis
endemic in some tropical and subtropical areas that is caused by a
group of dematiaceous fungi [1]. Fonsecaea pedrosoi is the most
frequent etiological agent. Patients are infected through the inoc-
ulation of hyphae or conidia following transcutaneous trauma.
Clinically, the lesions evolve progressively with erythema, pap-
ules, nodules, verrucous plaques, and/or ulcerations. Areas mostly
affected are the lower limbs, followed by the upper limbs and, less
commonly, the buttocks, trunk, and face. CBM is difﬁcult to treat
and has a low cure rate [2]. Many therapeutic approaches have
been reported, including intravenous (amphotericin B) or oral
(ie, 5-ﬂuorocytosine, itraconazole, and terbinaﬁne) antifungals,
surgical excision, and physical treatments (ie, cryotherapy and
thermotherapy), used alone or in combination. However, there
is currently no gold standard therapy for CBM. The few treat-
ment trials available report widely variable success rates, with
some studies reporting relapses in up to 80% of patients [2].
We recently explored the mechanisms underlying suscepti-
bility to infection with F. pedrosoi, using mouse models [3].
We discovered an underlying defect in innate recognition of
this organism by Toll-like receptors (TLRs) that could be re-
stored by exogenous administration of TLR agonists, including
imiquimod. Remarkably, such treatment resolved the infection
in mice without adverse effects [3].
Imiquimod, an imidazoquinoline, is a synthetic compound
with potent antiviral, antitumor, and immunoregulatory prop-
erties that stimulates both the innate and acquired immune
pathways through activation of TLR7. Imiquimod (Aldara;
3M Pharmaceuticals) was approved in 1997 by the US Food
and Drug Administration for topical treatment of external ano-
genital warts, actinic keratosis, and superﬁcial basal cell carcino-
ma [4]. Besides these approved indications, there have been
sporadic case reports and studies suggesting its effectiveness
in the treatment of other infectious and noninfectious cutane-
ous diseases, including cutaneous leishmaniasis [5]. Here, we
present evidence that topical administration of imiquimod has
a beneﬁcial effect in the management of CBM.
CASE REPORTS
The clinical features, diagnosis, histopathological ﬁndings,
treatments, and clinical courses for all patients are summarized
in Table 1.
Case 1
Case 1 was a 71-year-old man with a 2-year history of a lesion
on the right forearm (Figure 1A). Culture of a smear of the le-
sion yielded F. pedrosoi. Topical imiquimod 5% (5 times/week)
and itraconazole (200 mg/day) were prescribed. After 2 weeks,
the inﬂammatory aspect of the lesion was exacerbated, with a
more inﬁltrated and verrucous surface and more enlarged and
erythematous margins (Figure 1). Histopathological analysis re-
vealed a lichenoid lymphocytic inﬁltrate in the dermis (Fig-
ure 1B). No sclerotic bodies or other fungal structures were
identiﬁed in this biopsy section. After 7 months of the combina-
tion treatment, the exacerbated inﬂammatory process had sub-
sided, leaving a healing aspect (Figure 1). After 10 months of
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Table 1. Summary of Data From the Patients With Chromoblastomycosis Treated With Imiquimod Alone or in Combination With Oral
Antifungals
Variable Case 1 Case 2 Case 3 Case 4
Clinical features Erythematous infiltrated and
verrucous lesion with crusts
on right forearm for 2 y
Erythematous and
infiltrated lesion with a
keratotic and verrucous
elevated surface with
black dots on the
dorsum of right hand for
3 y
Erythematous and infiltrated
verrucous plaque lesion
with black dots on the
surface of the dorsum of
left hand for 6 y
Erythematous and
infiltrated lesion with
verrucous surface on the
right wrist for 5 y
Diagnosis F. pedrosoi on culture of
smear of the lesion
F. pedrosoi on culture of
smear of the lesion
F. pedrosoi on culture of
smear of the lesion
F. pedrosoi on culture of
smear of the lesion
Histopathological
findings on
admission
Epidermis: hyperkeratosis
with acanthosis,
spongiosis, and
microabscesses; dermis:
lymphohistiocytic
inflammatory infiltrate with
plasma cells, Langerhans-
type giant cells, and
granulomas containing
sclerotic cells
Hyperkeratosis, vacuolar
degeneration of the
basal layer, clusters of
Langerhans cells, and
giant cells containing
sclerotic cells
Epidermal acanthosis and
hyperkeratosis in a pseudo-
epitheliomatous pattern;
dermis: chronic
inflammatory infiltrate with
high numbers of
neutrophils and several
sclerotic cells
Epidermis: hyperkeratosis,
acanthosis, vacuolar
degeneration of the
basal layer, and
microabscesses;
dermis: granulomatous
infiltrate with giant cells
containing sclerotic cells
Prior treatment
(duration in mo)
. . . ITRA (7) ITRA + TERB (12) . . .
Treatment (duration
in mo)
IMQ+ ITRA (17) IMQ (6) IMQ+ ITRA + TERB (6) IMQ (6)
Inflammatory
exacerbation
Diagnosed at week 2 after
treatment; biopsy showed
lichenoid infiltration
Diagnosed at week 4 after
treatment
Persisted up to 4 mo after
treatment initiation
Diagnosed at week 4 after
treatment; biopsy
showed lichenoid
infiltration
Clinical course Cure after 20 mo of
posttreatment follow-up
Clinical improvement with
healed aspect but still
positive for fungi; oral
antifungal treatment
(ITRA + TERB) was
associated
Partial improvement; still
receiving treatment
Healed aspect except for a
small area still positive
for fungi; oral antifungals
(ITRA + TERB)
administered for an
additional 9 mo resulted
in complete healing,
with negative results of
tests for fungi
Abbreviations: F. pedrosoi, Fonsecaea pedrosoi; IMQ, topical imiquimod 5%; ITRA, itraconazole; TERB, terbinafine.
Figure 1. A, Pictures of the lesion on the forearm of case 1 before and during treatment with topical imiquimod 5% plus itraconazole 200 mg/day, as
indicated. B, Findings of hematoxylin-eosin staining of the chromoblastomycosis lesion from case 1 before (left; original magniﬁcation × 100) and during
(right; original magniﬁcation × 200) treatment with topical imiquimod and itraconazole.
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treatment, the lesion further improved, presenting a fully healed
aspect. Both treatments were then halted, and by 20 months after
treatment only a superﬁcial scar could be seen (Figure 1). Find-
ings of direct mycological examination was negative.
Case 2
Case 2 was a 70-year-old man with a 3-year history of a progres-
sive lesion on the dorsum of the right hand (Supplementary Fig-
ure 1). Mycological examination of the lesion revealed sclerotic
cells, which, on culture, yielded F. pedrosoi. The patient had
been treated with itraconazol (400 mg/day) for 7 months, with
no improvement. Treatment with topical imiquimod 5% 5
times weekly was started. Four weeks later, there was enhance-
ment in the verrucous and inﬁltrative aspect of the lesion, as ob-
served in the ﬁrst patient (Supplementary Figure 1). This aspect
was transitory, and by 14 weeks there was resolution of this in-
ﬂammatory response and marked improvement of the lesion
(Supplementary Figure 1). By 6 months, the lesion was apparently
healed (Supplementary Figure 1). However, direct mycological ex-
amination of material obtained by vigorously scraping the lesion
still yielded fungi. These organisms differed from the typical scle-
rotic bodies (with yeast-like form and binary division) seen before
treatment and presented as elongated ﬁlamentous forms (Supple-
mentary Figure 2). Because of the persistent presence of fungi, oral
antifungals (itraconazole 400 mg and terbinaﬁne 250 mg daily)
were then administered along with continued topical application
of imiquimod. At the last visit, after 3 months of the combination
treatment, the patient presented with only an erythematous cica-
tricial macula, but the mycological examination was still positive.
Case 3
Case 3 was a 46-year-old man with a 6-year history of a plaque
lesion on the left hand (Supplementary Figure 3). Sclerotic cells
were identiﬁed on direct mycological examination and by histo-
pathological analysis (not shown). The patient was treated with
itraconazole (400 mg) plus terbinaﬁne (250 mg) daily for 1 year,
with no improvement. Topical application of imiquimod 5% 5
times weekly was introduced in association with the orally ad-
ministered drugs. As in the previous cases, treatment with imi-
quimod resulted in increases in the erythematous and verrucous
aspects of the lesion that persisted up to 4 months of the com-
bination treatment, after which the lesion gradually decreased in
size (Supplementary Figure 3). Direct mycological examination
of the lesion showed atypical ﬁlamentous sclerotic bodies, as ob-
served in case 2. By 6 months, the lesion showed partial im-
provement, with reductions in the inﬂammatory process and
the number of black dots (Supplementary Figure 3).
Case 4
Case 4 was a 71-year-old man with a 5-year history of a lesion
on the right wrist (Supplementary Figure 4). Mycological
examination and histopathological analysis of the lesion
revealed sclerotic cells. The patient was treated with topical imi-
quimod 5% cream as a monotherapy 4 times weekly. Four
weeks later, there was an exacerbation of the inﬂammatory
and verrucous aspect of the lesion (Supplementary Figure 4)
that, on histopathological analysis, coincided with the presence
of a lichenoid lymphocytic inﬁltrate in the dermis, which dis-
rupted the dermal-epidermal junction in some places (Supple-
mentary Figure 5). Thereafter this inﬂammatory process
gradually subsided, and by 6 months the lesion was healed
except for a small area located at the medial border, which
still presented a slightly verrucous aspect (Supplementary Fig-
ure 4). Direct mycological examination of this area showed few
fungal cells with elongated ﬁlamentous forms. We then pre-
scribed itraconazole (200 mg) plus terbinaﬁne (250 mg) daily
in addition to the topical treatment with imiquimod. At the
last visit, 9 months after initiation of the combination treat-
ment, the lesion was in most part cicatricial, and mycological
examination of the small verrucous area had negative ﬁndings.
DISCUSSION
Here we have reported ﬁndings about the applicability of using
topical imiquimod as a treatment for CBM. The ﬁrst case dem-
onstrated that imiquimod could modify and accelerate the re-
sponse to conventional antifungal treatments. This encouraged
us to test imiquimod in the treatment of patients in whom anti-
fungal drugs yielded poor responses. In both patients in whom
oral antifungals (itraconazole plus terbinaﬁne) failed to induce
improvement of the lesions (cases 2 and 3), the initiation of top-
ical imiquimod treatment yielded marked improvement. In the
fourth patient, imiquimod therapy alone resulted in a sharp clin-
ical improvement but was apparently not able to completely erad-
icate the fungus. Of note, none of our patients reported any of the
side effects occasionally related to topical imiquimod use, such as
itching and a burning sensation [6].
Two interesting observations emerged from this study. In
cases 2, 3, and 4, direct mycological examination of the lesion
during imiquimod treatment showed that the sclerotic cells
changed their morphology from the typical yeast form with bi-
nary division, normally seen in lesions, to an elongated ﬁlamen-
tous form that has not been previously reported. This change in
morphology is likely to represent a fungal response to the new
pattern of local immune reactivity induced by imiquimod. In all
patients we observed a transitory exacerbation of the verrucous
and inﬁltrative characteristics of the lesion that preceded its
gradual evolution to healing. In the patients who had a concom-
itant histopathological reevaluation, the inﬂammatory exacer-
bation coincided with a high inﬂux of lymphocytes and
histiocytes, characterizing a lichenoid reaction. This inﬁltrate
denotes a change in the pattern of the inﬂammatory response
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toward an augmented cellular immunity and may be related to
the previously described property of imiquimod of inducing
psoriasis-like skin inﬂammation [7]. This inﬂammation
was characterized by epidermal hyperproliferation, abnormal
differentiation, epidermal accumulation of neutrophils in
microabscesses, neoangiogenesis, and inﬁltrates consisting of
CD4+ T cells, CD11c+ dendritic cells, and plasmacytoid den-
dritic cells.
Imiquimod is an immune response modiﬁer that increases
local cytokine production, with a subsequent activation of
both the innate and adaptive immune systems [8]. It has been
shown that patients with CBM may present T-helper type 1 hy-
poresponsiveness to F. pedrosoi antigens [9].This deﬁciency was
only partial and transitorily restored with conventional treat-
ments [10], an observation that may help explain the high
rate of relapses. Innate immunity mechanisms apparently fail
to control the infection and to instruct appropriate adaptive im-
mune responses, probably contributing to the chronic nature of
the infection [3]. Activated macrophages are unable to kill the
conidia, although they may present some fungistatic activity
[11]. Thus, as we found in our animal models [3], a defect
in innate recognition results in a failure to mount robust
inﬂammatory responses and causes susceptibility to infection.
Topical application of imiquimod overcomes this defect,
enhancing inﬂammatory responses that lead to clearance of
the pathogen and resolution of the infection. Such defects
could also underlie susceptibility to other subcutaneous myco-
ses like eumycetoma, sporotrycosis, hyalohyphomycosis, and as
such these mycoses may also beneﬁt from administration of
topical imiquimod [12].
Further studies using larger number of patients are required
to conﬁrm the beneﬁcial effect of imiquimod observed here.
These studies should also address the important issues of opti-
mal dosage and treatment duration. Nevertheless, despite the
limitations of a study involving a few patients, we believe that
our observations strongly suggest the use of this topical immu-
nomodulator as an adjuvant in the therapy of CBM.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org). Supplementary materials consist of data pro-
vided by the author that are published to beneﬁt the reader. The posted ma-
terials are not copyedited. The contents of all supplementary data are the
sole responsibility of the authors. Questions or messages regarding errors
should be addressed to the author.
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